All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab Followed By Pembrolizumab Maintenance Demonstrates Efficacy in MIBC

August 27th 2025

Neoadjuvant sacituzumab govitecan plus pembrolizumab with adjuvant/maintenance pembrolizumab led to high cCR rates in MIBC.

Perioperative Tislelizumab Wins EU Approval for Resectable NSCLC at High Risk of Recurrence

August 27th 2025

The European Commission approved neoadjuvant tislelizumab plus chemotherapy, followed by adjuvant tislelizumab, for resectable non–small cell lung cancer.

Adjuvant Abemaciclib Plus Endocrine Therapy Improves OS in High-Risk HR+/HER2– Breast Cancer

August 27th 2025

The addition of abemaciclib to endocrine therapy after surgery improved OS in patients with HR-positive, HER2-negative breast cancer with positive nodes.

Federal Funding Cuts Spark Concern Over Future of Cancer Research and Care in United States

August 27th 2025

Following cuts to federal funding for health agencies, concerns about the long-term consequences for research programs in the US are escalating.

UGN-102 Redefines Treatment Standards for Low-Grade, Intermediate-Risk NMIBC

August 27th 2025

William C. Huang, MD, discusses the FDA approval of UGN-102 for the treatment of patients with recurrent, low-grade, intermediate-risk NMIBC.

European Commission Greenlights UM171 Cell Therapy for Hematologic Malignancies

August 27th 2025

UM171 cell therapy has earned European Commission approval for the treatment of patients with hematologic malignancies requiring HSCT.

Ivonescimab Plus Chemo Boosts OS in Pretreated EGFR+ NSCLC

August 26th 2025

Ivonescimab plus chemotherapy improved overall survival in previously treated, advanced non–small cell lung cancer harboring EGFR mutations.

Researchers Build Real-World External Control Arm to Accelerate HER2+ Breast Cancer Drug Development

August 26th 2025

Jessica Paulus, ScD, discusses the incorporation of an external control arm into the analysis of a phase 2 trial in HER2-positive breast cancer.

Prosthetic Embodiment Research Could Improve Outcomes After Amputation in Sarcomas

August 26th 2025

R. Lor Randall, MD, FACS, discusses prosthetic design, embodiment strategies, and research to enhance function post-amputation in sarcoma management.

Trastuzumab Deruxtecan Approved in Japan for HER2-Low or -Ultralow Metastatic Breast Cancer

August 26th 2025

Trastuzumab deruxtecan has been approved in Japan for patients with HR+, HER2-low or -ultralow metastatic breast cancer.

Cancer's Progress Detailed by 3D Genomic Maps

August 26th 2025

New tool by Yale researchers charts journey from pre-cancerous to advanced disease in animal models.

FDA Grants Fast Track Designation to Stenoparib for Advanced Ovarian Cancer

August 26th 2025

Stenoparib receives FDA fast track designation for the treatment of patients with advanced ovarian cancer.

A New Era In Multiple Myeloma Treatment: Advances and Future Directions

August 26th 2025

The emergence of immunotherapies and targeted agents has ushered in a new era in relapsed/refractory multiple myeloma.

Rina-S Wins FDA Breakthrough Therapy Designation for Advanced or Recurrent Endometrial Cancer

August 26th 2025

The FDA has granted breakthrough therapy designation to rinatabart sesutecan for the treatment of patients with advanced or recurrent endometrial cancer who have disease progression on or following standard-of-care therapy.

4 Ways Oncologists Use Social Media to Debunk Myths and Dispel Misinformation

August 26th 2025

Eric K. Singhi, MD, and Shruti Patel, MD, discuss how they extend beyond the walls of their clinic to provide accurate cancer updates on social media.

Dermatologists Guide Oncology Teams to Recognize and Treat Breast Cancer Treatment–Associated Skin AEs

August 26th 2025

Jonathan Leventhal, MD, discusses the prevalence of breast cancer treatment–associated dermatologic AEs and the need for multidisciplinary management.

HRR Mutation Analysis Opens Door for Future Research Directions in Metastatic Prostate Cancer

August 25th 2025

David Olmos, MD, PhD, discusses how data on the incidence of HRR alterations in metastatic prostate cancer can inform future research.

Elranatamab/Daratumumab/Lenalidomide Delivers Strong Response Rates in Transplant-Ineligible Myeloma

August 25th 2025

Meletios A. Dimopoulos, MD, discusses the efficacy and safety of elranatamab plus daratumumab and lenalidomide in transplant-ineligible multiple myeloma.

Cancer-Associated Nerve Injury Leads to Chronic Inflammation and Immunotherapy Resistance

August 25th 2025

A study finds cancer cells break down protective nerve coverings, leading to nerve injury and chronic inflammation.

FDA Grants Breakthrough Therapy Designation to Rusfertide for Erythrocytosis in Polycythemia Vera

August 25th 2025

Rusfertide earned an FDA breakthrough designation for polycythemia vera based on findings from the phase 3 VERIFY study.